Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 670 results for kidney or kidneys or renal

  1. Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

    Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors.

  2. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

  3. Dapagliflozin for treating chronic kidney disease (TA775)

    Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.

  4. Renal cell carcinoma Pathways Pilot [ID6186]

    In development [GID-TA11186] Expected publication date: TBC

  5. Routine preoperative tests for elective surgery (NG45)

    This guideline covers routine preoperative tests for people aged over 16 who are having elective surgery. It aims to reduce unnecessary testing by advising which tests to offer people before minor, intermediate and major or complex surgery, taking into account specific comorbidities (cardiovascular, renal and respiratory conditions and diabetes and obesity). It does not cover pregnant women or people having cardiothoracic procedures or neurosurgery.

  6. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  7. Kidney conditions: CKD and eGFR (IND233)

    This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a–G5 (on the register, within the preceding 12 months) who had eGFR measured on at least 2 occasions separated by at least 90 days, and the second test within 90 days before the diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM215.

  8. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 20 November 2024

  9. Robot-assisted kidney transplant (IPG609)

    Evidence-based recommendations on robot-assisted kidney transplant in adults. This involves the surgeon using a robot to help with a kidney transplant.

  10. Kidney conditions: CKD urine albumin:creatinine ratio (IND144)

    This indicator covers the percentage of patients on the CKD register whose notes have a record of a urine albumin:creatinine ratio (or protein:creatinine ratio) test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM109

  11. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

  12. Kidney conditions: AKI register (IND174)

    This indicator covers establishing and maintaining a register of all patients who have had an episode of AKI. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM152

  13. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)

    NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .

  14. Kidney conditions: CKD register (3a to 5) (IND129)

    This indicator ensures the contractor establishes and maintains a register of patients aged 18 years or over with chronic kidney disease (CKD) with classification of categories G3a to G5 (previously stage 3 to 5). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM83

  15. Kidney conditions: eGFR for long-term NSAID use (IND232)

    This indicator covers the percentage of patients (excluding those on the CKD register) prescribed long-term (chronic) oral non-steroidal anti-inflammatory drugs (NSAIDs) who have had an eGFR measurement in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM214.